Red Light Holland seeks to enter the (legal) medicinal psilocybin market in Oregon.
Exploring the companies and themes that make up this emerging and exciting new sector
Optimi Health Finalizes Planned Build-Out of Mushroom Production and Research Facility
Optimi Health gets closer to completion of its 20,000 sq. ft. production and research facility in British Columbia.
Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1
Psyched Wellness continues pre-clinical work on its AME-1 extract.
Champignon Brands Announces Revocation of Cease Trade Orders
Champignon Brands has had its Cease Trade Order lifted and can resume trading on the CSE effective April 23, 2021 (symbol: SHRM).
MindMed To Commence Trading on Nasdaq
MindMed Inc (CAN:MMED / US:MMEDF) has received approval to commence trading on the NASDAQ starting April 27th. Symbol: MNMD.
Countdown To The atai IPO Begins: atai Files For $100m IPO Financing
With atai Life Sciences filing for a $100 million IPO financing, the countdown to IPO day has begun.
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Low share prices. VERY low trading volumes. The slump in psychedelic stocks in 2021 looks a lot like the slump in 2020.
MINDCURE (CSE: MCUR | OTC: MCURF) Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions
LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback
Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction
Cybin has successfully demonstrated proof of concept for two new drug candidates in internal testing as it moves toward IND status.
Psychedelics are transforming the way we understand depression and its treatment
Mental illness is the 21st century’s leading cause of disability, affecting an estimated billion people across the world.
Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back
Cybin adds several experts in mental health to its Clinical Advisory Board.
Psilocybin’s complicated relationship with creativity revealed in new placebo-controlled neuroimaging study
People under the influence of psilocybin — the active component of magic mushrooms — report having more profound and original thoughts, but tend to score lower on cognitive tests of creative ability, according to new research published in Translational Psychiatry.